• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by IsoRay Inc.

    1/22/24 4:17:28 PM ET
    $ISR
    Medical Specialities
    Health Care
    Get the next $ISR alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0000728387
    Isoray, Inc.
    IsoRay, Inc.
    CENTURY PARK PICTURES CORP
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Perspective Therapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Perspective Therapeutics, Inc.
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Seattle WASHINGTON 98121 2066760900

    3. Related Persons

    Last Name First Name Middle Name
    Spoor Johan (Thijs)
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Woods Lori
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Morich Frank
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Henson Heidi
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Williamson III Robert
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hunt Jonathan
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Puhlmann Markus
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Austin Mark
    Street Address 1 Street Address 2
    2401 Elliott Avenue Suite 320
    City State/Province/Country ZIP/PostalCode
    Seattle WASHINGTON 98121
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-01-08    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $20,846,671 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $20,846,671 USD
    or    Indefinite
    Total Amount Sold $20,846,671 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Based on 56,342,355 shares of common stock at $0.37 per share.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Perspective Therapeutics, Inc. /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer 2024-01-22

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $ISR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISR

    DatePrice TargetRatingAnalyst
    9/14/2021$1.25Outperform
    Northland Capital Markets
    More analyst ratings

    $ISR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Initial Results From First Patient Dosed With Perspective Therapeutics' Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

    RICHLAND, Wash. & CORALVILLE, Iowa, Feb. 22, 2023 (GLOBE NEWSWIRE) --  Perspective, Therapeutics, Inc. (formerly known as "Isoray, Inc.") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis. Dr Vikas Prasad presented the results at the 2023 PET Radiotracer Translation and Resource Center (PET-RTRC) Work

    2/22/23 5:02:57 PM ET
    $CATX
    $ISR
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

    RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery

    2/16/23 4:05:02 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

    Company's focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business as Perspective Therapeutics, Inc., along with a new brand identity effective immediately. Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its

    2/7/23 5:48:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital Markets initiated coverage on Isoray with a new price target

    Northland Capital Markets initiated coverage of Isoray with a rating of Outperform and set a new price target of $1.25

    9/14/21 8:21:18 AM ET
    $ISR
    Medical Specialities
    Health Care

    Lake Street initiated coverage on IsoRay with a new price target

    Lake Street initiated coverage of IsoRay with a rating of Buy and set a new price target of $3.00

    2/18/21 8:47:05 AM ET
    $ISR
    Medical Specialities
    Health Care

    HC Wainwright & Co. reiterated coverage on Isoray with a new price target

    HC Wainwright & Co. reiterated coverage of Isoray with a rating of Buy and set a new price target of $2.10 from $1.25 previously

    2/10/21 6:11:10 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    SEC Filings

    View All

    IsoRay Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    2/5/24 4:34:33 PM ET
    $ISR
    Medical Specialities
    Health Care

    SEC Form D filed by IsoRay Inc.

    D - Perspective Therapeutics, Inc. (0000728387) (Filer)

    1/22/24 4:17:28 PM ET
    $ISR
    Medical Specialities
    Health Care

    IsoRay Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    1/22/24 4:10:45 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    2/1/24 4:53:13 PM ET
    $ISR
    Medical Specialities
    Health Care

    Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/30/24 4:57:17 PM ET
    $ISR
    Medical Specialities
    Health Care

    Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/26/24 5:40:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    2/1/24 4:53:13 PM ET
    $ISR
    Medical Specialities
    Health Care

    Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/30/24 4:57:17 PM ET
    $ISR
    Medical Specialities
    Health Care

    Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/26/24 5:40:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

    RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery

    2/16/23 4:05:02 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

    RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. "The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders. It provides us with the opportunity to build on Isoray's existing business with a pipeline of very

    11/10/22 4:05:00 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

    RICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022. To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002

    10/31/22 8:14:00 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Leadership Updates

    Live Leadership Updates

    View All

    Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing

    RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort's appointment adds key expertise. "I am very excited to welcome Donna to the Isoray team. Donna brings some twenty-five years of experience in driving increased company revenue and in building and leading sales and marketing teams. Donna also brings a keen understanding of radiation therapy sequencing, and combination therapy with oncologic agents including immunotherapy to her role at Isoray." Woods concluded, "We believe Donna's proven d

    4/13/21 8:13:00 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IsoRay Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    9/18/23 9:20:56 PM ET
    $ISR
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by IsoRay Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    9/18/23 8:02:56 PM ET
    $ISR
    Medical Specialities
    Health Care